Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients

Although cholesterol has been involved in the pathophysiology of Alzheimer disease (AD), its distribution in the cerebral cortex over the course of AD is unknown. We describe an original method to quantify cholesterol distribution using time-of-flight secondary ion mass spectrometry imaging. Cholesterol was unevenly distributed along the cortical thickness, being more abundant close to the white matter, in both control and AD cases. However, the mean cholesterol signal was significantly higher in the lower half of the cortex in AD samples compared to controls. This increase, when converted into cortical layers, was statistically significant for layers III and IV and did not reach significance in layers V + VI, the variability being too high at the interface between grey and white matter. The density of neurofibrillary tangles and of senile plaques was not statistically linked to the abundance of cholesterol. Cholesterol overload thus appears a new and independent alteration of AD cerebral cortex. The structure in which cholesterol accumulates and the mechanism of this accumulation remain to be elucidated.

[1]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[2]  S. Melov,et al.  Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. , 2005, The Journal of clinical investigation.

[3]  P. R. Hof,et al.  Distribution of cortical neurofibrillary tangles in progressive supranuclear palsy: A quantitative analysis of six cases , 2004, Acta Neuropathologica.

[4]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[5]  Douglas Walker,et al.  Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. , 2002, Biochemistry.

[6]  L. Lue,et al.  Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. , 2008, Neurobiology of disease.

[7]  F. Pfrieger Role of cholesterol in synapse formation and function. , 2003, Biochimica et biophysica acta.

[8]  E. Weibel Practical methods for biological morphometry , 1979 .

[9]  C. Gottfries,et al.  Membrane Components Separate Early-Onset Alzheimer's Disease From Senile Dementia of the Alzheimer Type , 1996, International Psychogeriatrics.

[10]  T. Ohm,et al.  Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons , 2001, Acta Neuropathologica.

[11]  J. Cleary,et al.  Amyloid beta-peptide1-40 increases neuronal membrane fluidity: role of cholesterol and brain region. , 2001, Journal of lipid research.

[12]  J. Morrison,et al.  Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  C. Duyckaerts,et al.  Enrichment of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by mass spectrometry , 2010, Journal of Lipid Research.

[14]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[15]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[16]  J. Rossier,et al.  Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. , 2010, Biochimica et biophysica acta.

[17]  Charles Duyckaerts,et al.  Tau, paired helical filaments and amyloid in the neocortex: a morphometric study of 15 cases with graded intellectual status in aging and senile dementia of Alzheimer type , 2004, Acta Neuropathologica.

[18]  C. Duyckaerts,et al.  Laminar distribution of neocortical senile plaques in senile dementia of the alzheimer type , 2004, Acta Neuropathologica.

[19]  E. Ikonen,et al.  Caveolins and Cellular Cholesterol Balance , 2000, Traffic.

[20]  C. Duyckaerts,et al.  Local cholesterol increase triggers amyloid precursor protein‐Bacel clustering in lipid rafts and rapid endocytosis , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  Yu-Min Kuo,et al.  Increased Aβ Peptides and Reduced Cholesterol and Myelin Proteins Characterize White Matter Degeneration in Alzheimer's Disease† , 2002 .

[22]  M. Dhenain,et al.  Morphological and chemical studies of pathological human and mice brain at the subcellular level: Correlation between light, electron, and nanosims microscopies , 2007, Microscopy research and technique.

[23]  D. Touboul,et al.  Structural analysis of secondary ions by post-source decay in time-of-flight secondary ion mass spectrometry. , 2006, Rapid communications in mass spectrometry : RCM.

[24]  D. Touboul,et al.  Micrometric molecular histology of lipids by mass spectrometry imaging. , 2011, Current opinion in chemical biology.

[25]  John Woulfe,et al.  Cholesterol retention in Alzheimer's brain is responsible for high β- and γ-secretase activities and Aβ production , 2008, Neurobiology of Disease.

[26]  J. Lausmaa,et al.  Mass spectrometric imaging of lipids in brain tissue. , 2004, Analytical chemistry.

[27]  B. Hagenhoff,et al.  Distribution of cholesterol and galactosylceramide in rat cerebellar white matter. , 2006, Biochimica et biophysica acta.

[28]  C. Duyckaerts,et al.  Cholesterol in the senile plaque: often mentioned, never seen , 2008, Acta Neuropathologica.

[29]  Rudolph E. Tanzi,et al.  Alzheimer's disease: the cholesterol connection , 2003, Nature Neuroscience.

[30]  M J Campbell,et al.  Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: a quantitative study of visual and auditory cortices , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[31]  F. Benes,et al.  Laminar-specific distribution and infrastructural detail of amyloid in the Alzheimer disease cortex visualized by computer-enhanced imaging of epitopes recognized by monoclonal antibodies. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Armstrong Laminar Distribution of β-Amyloid Deposits in Dementia With Lewy Bodies and in Alzheimer’s Disease , 2006 .

[33]  C. Duyckaerts,et al.  Cholesterol changes in Alzheimer's disease: methods of analysis and impact on the formation of enlarged endosomes. , 2010, Biochimica et biophysica acta.

[34]  Per Malmberg,et al.  Bioimaging TOF‐SIMS: localization of cholesterol in rat kidney sections , 2004, FEBS letters.

[35]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[36]  M. Mattson,et al.  Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C. Morris,et al.  The imaging and quantification of aluminium in the human brain using dynamic secondary ion mass spectrometry (SIMS) , 1992, Biology of the cell.

[38]  E. Ikonen,et al.  Functional rafts in cell membranes , 1997, Nature.

[39]  Marie-Claude Potier,et al.  Classification and basic pathology of Alzheimer disease , 2009, Acta Neuropathologica.

[40]  S. Melov,et al.  Alzheimer disease β-amyloid activity mimics cholesterol oxidase , 2005 .

[41]  David Touboul,et al.  Improvement of biological time-of-flight-secondary ion mass spectrometry imaging with a bismuth cluster ion source , 2005, Journal of the American Society for Mass Spectrometry.

[42]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[43]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[44]  D. Volmer,et al.  Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients , 2009, Neurobiology of Disease.

[45]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[46]  T. Ohm,et al.  Cholesterol and Tau Protein - Findings in Alzheimer’s and Niemann Pick C’s Disease , 2003, Pharmacopsychiatry.

[47]  F. Halgand,et al.  Tissue molecular ion imaging by gold cluster ion bombardment. , 2004, Analytical chemistry.

[48]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.